A postmarketing safety programme for generic ticlopidine is being considered by the US FDA

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 1999年 / 753卷 / 1期

关键词：

Public Health; Neutropenia; Thrombocytopenia; Monitoring Programme; Purpura;

D O I：

10.2165/00128415-199907530-00001

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[31] Pentosan associated retinal pigmentary changes: FDA’s perspective on an emerging postmarketing safety finding
Allison Lardieri
Karen Konkel
Lynda McCulley
S. Christopher Jones
David Moeny
Christine Nguyen
Catherine Sewell
Wiley Chambers
Adebola Ajao
[J]. International Urogynecology Journal, 2021, 32 : 2891 - 2897
[32] US FDA: fake warning letters being issued to consumers
[J]. Reactions Weekly, 2018, 1712 (1) : 6 - 6
[33] Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System
Li, Xingxing
Zhang, Lin
Hu, Sang
Liu, Dan
Hu, Bin
Ran, Jie
Lin, Xiaofang
Mao, Wei
Hu, Jing
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (02) : 256 - 268
[34] Consumers have been warned by the US FDA about a potentially harmful product labelled as “Generic Tamiflu” being sold over the Internet
[J]. Reactions Weekly, 2010, 1307 (1) : 3 - 3
[35] GnRH agonists: US FDA reviews CV safety
[J]. Reactions Weekly, 2010, 1300 (1) : 1 - 1
[36] US FDA reports new steps in drug safety
[J]. Reactions Weekly, 2007, 1138 (1) : 3 - 3
[37] Report on Drug Safety and the US FDA by the Institute of Medicine
Anthony W. Fox
[J]. International Journal of Pharmaceutical Medicine, 2006, 20 (5) : 289 - 291
[38] US FDA to encourage comparative safety claims of antidiabetics
[J]. Reactions Weekly, 1997, 682 (1) : 2 - 2
[39] US FDA and DCRI to collaborate on cardiac safety of drugs
[J]. Reactions Weekly, 2006, 1122 (1) : 2 - 2
[40] US FDA 2009 drug safety warnings analysed
[J]. Reactions Weekly, 2012, 1388 (1) : 4 - 4

← 1 2 3 4 5 →